Phase 2 Study of Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy: The REVISE Trial
The REVISE trial, a phase 2 study evaluating GenSight Biologics’ lenadogene nolparvovec in patients with Leber hereditary optic neuropathy, is expected to begin in January 2026.
Welcome to NeurologyLive®'s Clinical Trial in Focus. Every month, an ongoing clinical trial in the landscape of neurology is featured, highlighting the design of the study, the targeted patient population, the enrollment criteria, the primary and secondary end points, and its potential implications for clinical care. This month’s spotlight is the phase 2 REVISE trial (NCT07303296) of lenadogene nolparvovec (Lumevoq; GenSight Biologics), also known as GS010, for patients with Leber hereditary optic neuropathy (LHON), a rare genetic disorder that leads to bilateral vision loss.